NovaBay Pharmaceuticals to Hold Third Quarter 2018 Conference Call on November 14, 2018

Nov. 7, 2018 11:50 UTC

EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay Pharmaceuticals Inc (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that it will report third quarter 2018 financial results after market close on Wednesday, November 14. Management will hold an investment community conference call that day to discuss financial results and provide a Company update.

 
DATE:       Wednesday, November 14
TIME:       4:30 p.m. ET / 1:30 p.m. PT
DIAL IN:       800-608-8202 from within the U.S.
        702-495-1913 from outside the U.S.
        Enter conference identification number 5709629
 

The live call also will be available at http://novabay.com/investors/events. A replay of the call will be available beginning two hours after its completion through 11:59 p.m. Eastern time November 20, 2018, by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 5709620. The call will also be archived at http://novabay.com/investors/events.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for the wound care market and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in dermatology and urology.

Socialize and Stay informed on NovaBay’s progress:
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website

NovaBay Contacts
For NovaBay Avenova purchasing information:
Please Call us toll free: 1-800-890-0329 or email sales@avenova.com.
www.Avenova.com

 

Contacts

NovaBay Pharmaceuticals, Inc.
Jack McGovern, 510-899-8800
Chief Executive Officer and
Chief Financial Officer
jmcgovern@novabay.com
or
Investor Contact
LHA Investor Relations
Jody Cain, 310-691-7100
jcain@lhai.com

 

 
 

Source: NovaBay Pharmaceuticals, Inc.

Back to news